Notables Calls notes that Leerink has set a new price target of $30 on Human Genome Sciences due to the likely hood of positive Phase II trial data for BLISS-76.
$30 Price Target on Human Genome Sciences
Posted by Tim | 12:10 PM | Human Genome Sciences | 0 comments »
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment